Not Signed In -
Carteolol Ophthalmic |
Ocupress |
Clinical Trial: A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients with Open-Angle Glaucoma or Ocular Hypertension
This study is no longer recruiting patients.
|
Purpose
The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Open-Angle Glaucoma Ocular Hypertension | Drug: Brimonidine Tartrate Ophthalmic Solution | Phase III |
MedlinePlus related topics: Eye Diseases; Glaucoma
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Study start: January 2003
Eligibility
Ages Eligible for Study: 2 Months and above, Genders Eligible for Study: Both
Criteria
- Patients of any race
- two (2) years of age or older
- of either sex
- diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)or ocular hypertension
Location Information
Texas
Alcon Call Center, Fort Worth, Texas, United States
More Information
Study ID Numbers: C-02-49
Record last reviewed: July 2003
Last Updated: October 13, 2004
Record first received: May 28, 2003
ClinicalTrials.gov Identifier: NCT00061529
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: July 2003
Last Updated: October 13, 2004
Record first received: May 28, 2003
ClinicalTrials.gov Identifier: NCT00061529
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
